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Abstract
At present, available treatments for Alzheimer's disease (AD) are largely unable to halt disease progression. Microglia,
the resident macrophages in the brain, are strongly implicated in the pathology and progressively degenerative nature of
AD. Specifically, microglia are activated in response to both β amyloid (Aβ) and neuronal damage, and can become a
chronic source of neurotoxic cytokines and reactive oxygen species (ROS). NADPH oxidase is a multi-subunit enzyme
complex responsible for the production of both extracellular and intracellular ROS by microglia. Importantly, NADPH
oxidase expression is upregulated in AD and is an essential component of microglia-mediated Aβ neurotoxicity.
Activation of microglial NADPH oxidase causes neurotoxicity through two mechanisms: 1) extracellular ROS produced
by microglia are directly toxic to neurons; 2) intracellular ROS function as a signaling mechanism in microglia to amplify
the production of several pro-inflammatory and neurotoxic cytokines (for example, tumor necrosis factor-α,
prostaglandin E2, and interleukin-1β). The following review describes how targeting NADPH oxidase can reduce a broad
spectrum of toxic factors (for example, cytokines, ROS, and reactive nitrogen species) to result in inhibition of neuronal
damage from two triggers of deleterious microglial activation (Aβ and neuron damage), offering hope in halting the
progression of AD.
Introduction
Alzheimer's disease (AD) affects more than 4 million peo-
ple in the United States [1] and an estimated 27 million
are affected worldwide [2]. Increasing with the aging pop-
ulation, the number of affected individuals is expected to
triple by 2050 [1]. AD is a devastating disease, aggressively
eroding the memory and cognitive function of patients
across time, while robbing families, friends, and caretak-
ers of their loved ones. At present, available treatments are
unable to halt the progression of AD, making the identifi-
cation of novel treatments for prevention and neuropro-
tection a pressing scientific concern. The following review
centers on the role of microglia, the resident innate
immune cells in the brain, and how this cell type contrib-
utes to progressive neuron damage, the role of NADPH
oxidase in deleterious microglial activation, and how we
may be able to target this key neurotoxic process to halt
neurodegenerative diseases such as AD.
Microglia and inflammation-mediated 
neurodegeneration
There is a wealth of evidence demonstrating that micro-
glia, the resident innate immune cells in the brain, can
become deleterious and damage neurons [3,4]. This proc-
ess is implicated as an underlying mechanism in diverse
neurodegenerative diseases, including AD [3,4]. While
microglial function is beneficial and mandatory for nor-
mal central nervous system functioning, microglia
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become toxic to neurons when they are over-activated and
unregulated [4]. Microglia are activated in response to
specific stimuli to produce pro-inflammatory factors (for
example, tumor necrosis factor (TNF)α, prostaglandin E2
(PGE2), and interferon-γ) and reactive oxygen species (for
example, •NO, H2O2, O2•-, ONOO-/ONOOH), which are
toxic to neurons [4,5]. Microglia actively monitor the
brain and can become activated to cause neuron damage
in response to two categories of stimuli. First, microglia
can identify pro-inflammatory triggers, such as β-amyloid
(Aβ), resulting in activation, the production of toxic fac-
tors, and neuron death/damage (Figure 1). Second, the
microglial response to neuronal damage can also become
toxic (Figure 1) [5]. Current evidence demonstrates that
the microglial response to neuronal damage can be long-
lived, self-perpetuating, and toxic to neurons [3,5,6] (Fig-
ure 1). This repeating cycle of the neurotoxic activation of
microglia in response to neuron injury is commonly
referred to as reactive microgliosis (Figure 1). In fact, it has
been proposed that deleterious microglial activation may
be propagated and potentially amplified throughout mul-
tiple neurodegenerative diseases, including AD [3].
Alzheimer's disease, microglial activation, and 
oxidative stress
Pathological diagnosis of AD is characterized by the iden-
tification of insoluble extracellular plaques containing Aβ
and intraneuronal neurofibrillary tangles in the cortical
region of the brain. The premise of microglia over-activa-
tion in AD has been supported by analysis of post mortem
brains from AD patients, where there is clear evidence of
microglial activation in association with lesions of senile,
amyloid plaques and neurofibrillary tangles [7,8]. In fact,
microglial activation occurs early in AD development,
before neuropil damage, supporting a contributing role of
microglia in disease pathology [9]. Further, the microglial
response to Aβ [10,11] and the senile plaques [12,13]
includes the production of toxic factors. For example,
TNFα [14], nitric oxide [15], and superoxide [11] are pro-
duced by microglia in response to Aβ. Epidemiological
studies have further supported the role of inflammation
in AD, where results have shown a decreased incidence
and severity of AD in patient populations treated with
nonsteroidal anti-inflammatory drugs (NSAIDs) [16-18].
Thus, evidence supports the presence of microglial activa-
tion in AD and that this may contribute to the pathology
of the disease [19], where Aβ is hypothesized to be a key
element in the pro-inflammatory mechanism.
Microglia-mediated neuron damageFigure 1
Microglia-mediated neuron damage. Microglia activation has been implicated in the progressive nature of Alzheimer's disease. 
Microglia can become deleteriously activated in response to disease-specific stimuli (amyloid-β (Aβ) oligomers, Aβ fibrils, and 
senile plaques) to produce a catalogue of factors, such as reactive oxygen species and cytokines that are toxic to neurons. In 
addition to disease-specific pro-inflammatory stimuli, neuronal damage/death can also activate microglia to produce these toxic 
factors. This continual and self-perpetuating cycle of neuronal damage/death followed by microglial activation is commonly 
referred to as reactive microgliosis and may be an underlying mechanism of the progressive nature of diverse neurodegenera-
tive diseases, including Alzheimer's disease. Although all forms of Aβ have yet to be tested in detail, NADPH oxidase (also 
called phagocytic oxidase (PHOX)) has been implicated as a key mechanism through which microglia damage neurons in 
response to Aβ and neuron damage/death. This figure is modified from Block et al. [3]. NO, nitric oxide; PGE2, prostaglandin 
E2; TNF, tumor necrosis factor.
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The amyloid hypothesis has been modified over time, but
the premise has remained that Aβ has a causative role in
AD pathology [20], both through direct toxicity to neu-
rons [21], and by causing neuronal damage through
microglial activation [20]. Aβ(1–40) and Aβ(1–42) are
the predominant forms of Aβ in the brain, and have been
implicated as active participants in the mechanism of AD
progression. Aβ(1–42) has been labeled as the more toxic
of the two prevalent Aβ peptides, and toxicity is depend-
ent upon the aggregation state of Aβ, and the mode of tox-
icity (that is, directly toxic to neurons or microglia-
mediated neurotoxicity) [20,22,23]. The aggregation state
of Aβ required to cause microglia activation and neuron
damage is disputed. For example, small, soluble oligom-
ers of Aβ have been shown to activate microglia [24], but
the majority of studies suggest that the larger, insoluble
Aβ aggregates, and fibrillized Aβ, are the more potent
stimuli [25,26]. Undoubtedly, Aβ has been shown to both
recruit and activate microglia [8,14,27], suggesting a criti-
cal role in AD progression.
In addition to microglial activation and cytokine produc-
tion, oxidative stress is closely associated with AD [28],
where early AD pathology shows evidence of oxidative
damage [29-31], indicating a potential role in disease
pathogenesis. The detailed mechanisms of how oxidative
stress causes AD are complex and poorly understood, but
AD-specific patterns of oxidative stress have been identi-
fied. For example, localized increases in carbonylated-, 4-
hydroxynonenal-, and 3-nitrotyrosine-modified proteins
have been reported in hippocampus and parietal cortex of
AD patient brains, demonstrating disease specific modifi-
cations due to reactive nitrogen species [32]. In fact, it has
been repeatedly demonstrated that increased levels of
nitrated proteins are present in AD brains [33-36], includ-
ing tau nitration [37], which indicates that an increase in
reactive nitrogen species affects AD pathology. Addition-
ally, protein oxidation is known to induce protein aggre-
gation, a process that has been hypothesized as a critical
mechanism contributing to tau tangle formation [31], Aβ
aggregation, and senile plaque formation [38]. Impor-
tantly, Aβ is also clearly indicated as a source of oxidative
stress [39], as Aβ activates microglia to produce extracellu-
lar superoxide [11,40]. Thus, while there may be several
sources and mechanisms, there is increasing support that
oxidative stress contributes to AD pathology, and that
microglia and Aβ may play an instigating role.
NADPH oxidase, oxidative stress, and neuronal 
damage
NADPH oxidase is a multi-subunit enzyme complex that
is activated during host defense in phagocytes, such as
microglia, to catalyze the production of superoxide from
oxygen. NADPH oxidase is a member of the NOX gene
family, also called NOX2 and phagocytic oxidase
(PHOX). The NADPH oxidase enzyme complex consists
of the membrane bound cytochrome b558 (p22PHOX and
the enzymatic subunit, gp91PHOX), several cytosolic pro-
teins (p47PHOX, p67PHOX, and p40PHOX), and the Rac G-
protein [41,42]. NADPH oxidase is activated when the
cytosolic subunits are phosphorylated and Rac is activated
in the cytosol, resulting in their translocation to the mem-
brane and formation of the active NADPH oxidase com-
plex with cytochrome b558 [41,42]. The end product of
the enzyme is superoxide.
Recently, NADPH oxidase has been associated with neu-
rodegenerative disorders and related complications. For
example, NADPH oxidase is activated in brains from AD
patients [43] and is upregulated in Parkinson's disease
[44]. Interestingly, reactive oxygen species (ROS) from
NADPH oxidase have also been shown to mediate Aβ-
induced cerebrovascular dysfunction [45]. It is not sur-
prising that several stimuli activate NADPH oxidase in
microglia to cause neuron damage, including Aβ [11,46],
amyloid precursor protein [47], rotenone [48], air pollu-
tion [49], paraquat [50], substance P [51], and α-synu-
clein [52]. Further, NADPH oxidase has been shown to
play a role in how reactive microgliosis (the microglial
response to neuron damage) causes additional neuron
damage [53]. Thus, evidence supports that NADPH oxi-
dase may be a common pathway of microglia-mediated
neuronal damage.
The NOX family of proteins is expressed on diverse cell
types and NADPH oxidase is present in microglia, neu-
rons, and astrocytes. However, NADPH oxidase is present
in lower amounts in cells that are not from the myeloid
lineage (for example, neurons and astrocytes). Addition-
ally, astrocytes and neurons do not express several recep-
tors that recognize and respond to stimuli that activate
NADPH oxidase in microglia, including MAC1 and sub-
sets of scavenger receptors. Further, while NADPH oxidase
can be activated in these alternative cell types, the result-
ing production of ROS is significantly lower than that of
microglia and other cells specialized for innate immunity.
Notably, a study using lipopolysaccharide (LPS) as a stim-
ulus of microglial activation showed that only NADPH
oxidase from microglia, and not astrocytes and neurons,
caused the NADPH oxidase-mediated neuron damage
[54]. Microglia derived from NADPH oxidase knockout
mice failed to produce extracellular superoxide, expressed
reduced pro-inflammatory profiles, and showed signifi-
cantly less intracellular ROS [54]. Thus, microglia are the
predominant source of NADPH oxidase-derived ROS and
targeting microglial NADPH oxidase may be an ideal
approach to attenuate deleterious activation [55].
In addition to damaging neurons through the production
of extracellular superoxide, NADPH oxidase also impacts
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neuron survival by regulating the microglial pro-inflam-
matory response [56]. The PHOX-ROS pathway refers to
the signaling mechanism resulting from the increase in
intracellular ROS in phagocytes as a response to NADPH
oxidase activation. The increase in intracellular ROS in
phagocytes, such as microglia, includes the production of
several radicals, including the superoxide anion, hydroxyl
radical, lipid hydroperoxides, and their by-products (for
example, H2O2) [57]. Normal cellular function and
metabolism results in the production of intracellular ROS
from multiple cellular sources, including mitochondrial
electron transport, xanthine oxidase, peroxisomes, and
the endoplasmic reticulum [57]. However, NADPH oxi-
dase contributes to a large proportion of intracellular ROS
in phagocytes in response to an immunological stimulus,
where approximately 50% of the LPS-induced intracellu-
lar ROS increase in microglia is due to NADPH oxidase
[54]. The relative contribution of NADPH oxidase to the
increase in microglial intracellular ROS is stimulus
dependent, as substance P-induced intracellular ROS is
largely dependent upon NADPH oxidase [51].
NADPH oxidase enhances pro-inflammatory gene expres-
sion through several downstream signaling molecules, for
example, protein kinase C, mitogen-activated protein
kinase activation, and nuclear factor-κB (NFκB) [58-60].
Thus, NADPH oxidase initiates an intracellular ROS sign-
aling pathway [61] that can activate microglia and amplify
the production of multiple pro-inflammatory cytokines,
such as TNFα [54] or PGE2 [62]. In fact, several triggers of
NADPH oxidase activation in microglia amplify pro-
inflammatory signaling. For example, gangliosides are
shown to activate microglia, where the production of
interleukin (IL)-1β, TNF-α, and inducible nitric oxide syn-
thase (iNOS) are attenuated by the addition of the
NADPH oxidase inhibitor diphenyleneiodonium (DPI)
[63]. Furthermore, both DPI and catalase (an enzyme that
catalyzes the decomposition of H2O2 to water and oxy-
gen) were shown to suppress LPS-induced expression of
cytokines (IL-1, IL-6, and TNFα), iNOS, mitogen-acti-
vated protein kinases, and NFκB phosphorylation [64]. In
addition to cytokine production, NADPH oxidase has also
been shown to mediate the morphological changes asso-
ciated with microglial activation [54]. Thus, intracellular
ROS play an essential role in the regulation of general
microglial activation.
Additionally, NADPH oxidase is reported to prime micro-
glia for enhanced sensitivity to additional stimuli. For
example, rotenone [65] and neuronal death [66] have
been shown to prime microglia through NADPH oxidase
to synergistically enhance cytokine production and neuro-
toxicity upon additional exposure to LPS. Thus, not only
does activation of NADPH oxidase amplify the microglial
pro-inflammatory response, it also changes this response
to additional stimuli, allowing a robust pro-inflammatory
response to previously innocuous stimuli. Taken together,
microglial NADPH oxidase activation, and the production
of ROS, have been implicated as critical regulators of
microglia-mediated neurotoxicity and represent ideal
therapeutic targets.
Anti-inflammatory therapy and Alzheimer's 
disease
Given the strong evidence for the presence of microglial
activation, oxidative stress, and pro-inflammatory factors
in AD [67], there has been a keen interest in the potential
therapeutic utility of anti-inflammatory drugs [68,69].
Unfortunately, while many epidemiological and animal
studies have supported the use of this approach, clinical
trials have not been successful.
The bulk of previous anti-inflammatory studies have
focused predominantly on NSAIDs [70]. Epidemiological
studies have shown that patients taking anti-inflamma-
tory medicine for rheumatoid arthritis were six times less
likely to develop AD [71]. Other epidemiological studies
have also shown that diets high in anti-oxidants may
decrease the risk of developing AD [72]. Additionally, a
separate epidemiological study shows that taking NSAIDs
for at least one month is associated with lower probability
of AD [73]. Interestingly, NSAIDs may also protect against
cognitive decline in the elderly without AD diagnosis [74].
However, only two pilot trials have shown some promise
[73,75], and the majority of clinical results for NSAIDS
have been disappointing. One explanation proposed for
the success of NSAIDs in both animal and epidemiologi-
cal studies, yet failure in clinical trails, is that NSAIDs may
be able to prevent disease, rather than treat symptoms
[73]. Another hypothesis is that the anti-inflammatory
compounds tested may not be focusing on the most dele-
terious and damaging consequences of microglial activa-
tion.
Neuroprotection and NADPH oxidase inhibitors
Traditional NSAIDs, such as indomethacin and aspirin,
target a single pro-inflammatory factor, such as PGE2,
where the target is the downstream result of the toxic
microglial pro-inflammatory response. However, micro-
glia produce several pro-inflammatory factors and ROS
[4], where successful inhibition of microglia-mediated
toxicity will likely require the attenuation of a broad spec-
trum of factors. To address this problem, our approach
has been to focus on regulating the microglial function
upstream, before the response becomes toxic, and to focus
on what we believe to be the most detrimental compo-
nent of microglial activation, NADPH oxidase activation
(Figure 2).
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Recently, several peptides (pituitary adenylate cyclase-
activating polypeptide, dynorphin, glycine-glycine-phe-
nylalanine, leucine enkephalin, and des-tyrosine leucine
enkephalin) [76-78], antibiotics (minocycline) [79], and
small molecules (dextromethorphin, statins, naloxone,
and sinolimine) [77,80,81] have been identified that
inhibit NADPH oxidase and are neuroprotective (Figure
2). For example, dextromethorphan (DXM) illustrates the
broad therapeutic utility of NADPH oxidase inhibitors
[82]. DXM is a noncompetitive N-methyl-d-aspartate
(NMDA) receptor antagonist that is widely and commer-
cially used as an antitussive agent, and is neuroprotective
through inhibition of microglial activation and NADPH
oxidase activation [83,84]. In addition, DXM has been
tested for a variety of conditions, and has shown activity
in ameliorating pain [85] and as a neuroprotectant against
focal ischemia [86]. In particular, DXM is noted to have
anti-inflammatory effects [87], and is reported to protect
against neuron damage through the inhibition of micro-
glial activation in methamphetamine-induced neurotox-
icity [88], and in studies of in vitro [83,89] and in vivo [90]
models of Parkinson's disease. While the NMDA inhibitor
dizocilpine maleate fails to inhibit NADPH oxidase, and
is not neuroprotective [84], a recent report showed that
the NMDA receptor antagonist memantine may also be
neuroprotective through microglia inhibition [91]. While
it is clear that DXM works through the inhibition of
NADPH oxidase [83,84], and inhibition of the NMDA
receptor does not always result in neuroprotection [89],
the role of the NMDA receptor in DXM inhibition of
NADPH oxidase remains unclear. Notably, DXM, statins,
and naloxone have a history of safe therapeutic use, sup-
porting that inhibition of NADPH oxidase is safe. For the
purpose of targeting this enzyme complex for the thera-
peutic treatment of neurodegenerative diseases, future
efforts will need to focus on the identification of both the
detailed mechanisms of NADPH oxidase inhibition and
developing more specific inhibitors.
NADPH oxidase inhibition targets deleterious microglial activationFigure 2
NADPH oxidase inhibition targets deleterious microglial activation. Increasing evidence points to NADPH oxidase (also called 
phagocytic oxidase (PHOX)) as a critical mechanism of microglia-mediated neuron damage. Traditional anti-inflammatory 
approaches focus on specific downstream targets, such as prostaglandin E2 (PGE2). However, targeting NADPH oxidase inhib-
its the global pro-inflammatory response further upstream in the process of neurotoxic microglial activation and is able to 
inhibit a broad spectrum of cytokines, nitric oxide, and reactive oxygen species to confer neuroprotection. At present, small 
molecules, peptides, anti-inflammatory cytokines, and an antibiotic have been identified that inhibit microglial NADPH oxidase 
and are neuroprotective. Further research is warranted to discover the mechanisms through which these seemingly diverse 
compounds work and to identify more specific inhibitors of this key neurotoxic pathway. This figure is modified from Zhang et 
al. [82]. IL, interleukin; TNF, tumor necrosis factor.
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Conclusion
Increasing evidence points to NADPH oxidase as a critical
component of deleterious microglial activation. Key com-
ponents of AD pathology, for example, Aβ fibrils and
plaques, can serve as triggers of microglial NADPH oxi-
dase activation and associated neuron damage. Addition-
ally, NADPH oxidase has been implicated in the
neurotoxic response of microglia to neuronal damage.
Activation of microglial NADPH oxidase causes neuron
damage through the production of neurotoxic extracellu-
lar ROS, enhancement of the global microglial pro-
inflammatory response, and the priming of microglia to
have a heightened sensitivity to previously innocuous
stimuli. In this manner, inhibiting NADPH oxidase may
target the progressive cycle of deleterious microglial acti-
vation that fuels progressive neurotoxicity. At present,
while 'old drugs' have been identified that are neuropro-
tective through their effects on NADPH oxidase, and may
be useful for current therapy, future research must focus
on elucidating the detailed molecular mechanisms of the
diverse list of NADPH oxidase inhibitors and then move
forward with developing more specific, potent, and safe
agents.
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